We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity (PRIMED-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02993991
Recruitment Status : Withdrawn (The study has been terminated due to a change in internal prioritization and not due to any safety concerns.)
First Posted : December 15, 2016
Last Update Posted : December 29, 2017
Mirati Therapeutics Inc.
Information provided by (Responsible Party):
University Health Network, Toronto

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Actual Primary Completion Date : December 21, 2017
Actual Study Completion Date : December 21, 2017